Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systematic review and meta-analysis

BACKGROUND: Gemcitabine (GEM) is the most widely utilized systemic agent in combination with radiation therapy (RT) for treating locally advanced pancreatic cancer (LAPC) in the concurrent setting. Despite recent interest in using two novel oral fluoropyrimidines (FUs), capecitabine and S-1, in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yong-Feng, Cao, Xiao-Hui, Bao, Chao-En, Wan, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646586/
https://www.ncbi.nlm.nih.gov/pubmed/26635481
http://dx.doi.org/10.2147/OTT.S91292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646586/
https://www.ncbi.nlm.nih.gov/pubmed/26635481
http://dx.doi.org/10.2147/OTT.S91292

Ejemplares similares